145 related articles for article (PubMed ID: 26675441)
21. Discovery of GDC-0853: A Potent, Selective, and Noncovalent Bruton's Tyrosine Kinase Inhibitor in Early Clinical Development.
Crawford JJ; Johnson AR; Misner DL; Belmont LD; Castanedo G; Choy R; Coraggio M; Dong L; Eigenbrot C; Erickson R; Ghilardi N; Hau J; Katewa A; Kohli PB; Lee W; Lubach JW; McKenzie BS; Ortwine DF; Schutt L; Tay S; Wei B; Reif K; Liu L; Wong H; Young WB
J Med Chem; 2018 Mar; 61(6):2227-2245. PubMed ID: 29457982
[TBL] [Abstract][Full Text] [Related]
22. Bruton's tyrosine kinase as a drug discovery target.
Pan Z
Drug News Perspect; 2008 Sep; 21(7):357-62. PubMed ID: 19259548
[TBL] [Abstract][Full Text] [Related]
23. Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis.
Kim KH; Maderna A; Schnute ME; Hegen M; Mohan S; Miyashiro J; Lin L; Li E; Keegan S; Lussier J; Wrocklage C; Nickerson-Nutter CL; Wittwer AJ; Soutter H; Caspers N; Han S; Kurumbail R; Dunussi-Joannopoulos K; Douhan J; Wissner A
Bioorg Med Chem Lett; 2011 Nov; 21(21):6258-63. PubMed ID: 21958547
[TBL] [Abstract][Full Text] [Related]
24. Potent and selective thiophene urea-templated inhibitors of S6K.
Ye P; Kuhn C; Juan M; Sharma R; Connolly B; Alton G; Liu H; Stanton R; Kablaoui NM
Bioorg Med Chem Lett; 2011 Jan; 21(2):849-52. PubMed ID: 21185721
[TBL] [Abstract][Full Text] [Related]
25. Finding the perfect spot for fluorine: improving potency up to 40-fold during a rational fluorine scan of a Bruton's Tyrosine Kinase (BTK) inhibitor scaffold.
Lou Y; Sweeney ZK; Kuglstatter A; Davis D; Goldstein DM; Han X; Hong J; Kocer B; Kondru RK; Litman R; McIntosh J; Sarma K; Suh J; Taygerly J; Owens TD
Bioorg Med Chem Lett; 2015 Jan; 25(2):367-71. PubMed ID: 25466710
[TBL] [Abstract][Full Text] [Related]
26. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
Asami T; Kawahata W; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
[TBL] [Abstract][Full Text] [Related]
27. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
28. Pyrrolo[2,3-b]pyridine derivatives as potent Bruton's tyrosine kinase inhibitors.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Aug; 23(15):4344-4353. PubMed ID: 26169764
[TBL] [Abstract][Full Text] [Related]
29. Bruton's Tyrosine Kinase Small Molecule Inhibitors Induce a Distinct Pancreatic Toxicity in Rats.
Erickson RI; Schutt LK; Tarrant JM; McDowell M; Liu L; Johnson AR; Lewin-Koh SC; Hedehus M; Ross J; Carano RA; Staflin K; Zhong F; Crawford JJ; Zhong S; Reif K; Katewa A; Wong H; Young WB; Dambach DM; Misner DL
J Pharmacol Exp Ther; 2017 Jan; 360(1):226-238. PubMed ID: 27821712
[TBL] [Abstract][Full Text] [Related]
30. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
31. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
32. Discovery of 4-Aminoquinoline-3-carboxamide Derivatives as Potent Reversible Bruton's Tyrosine Kinase Inhibitors for the Treatment of Rheumatoid Arthritis.
Yao X; Sun X; Jin S; Yang L; Xu H; Rao Y
J Med Chem; 2019 Jul; 62(14):6561-6574. PubMed ID: 31260299
[TBL] [Abstract][Full Text] [Related]
33. Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Angst D; Gessier F; Janser P; Vulpetti A; Wälchli R; Beerli C; Littlewood-Evans A; Dawson J; Nuesslein-Hildesheim B; Wieczorek G; Gutmann S; Scheufler C; Hinniger A; Zimmerlin A; Funhoff EG; Pulz R; Cenni B
J Med Chem; 2020 May; 63(10):5102-5118. PubMed ID: 32083858
[TBL] [Abstract][Full Text] [Related]
34. 2-Aminomethylthieno[3,2-d]pyrimidin-4(3H)-ones bearing 3-methylpyrazole hinge binding moiety: Highly potent, selective, and time-dependent inhibitors of Cdc7 kinase.
Kurasawa O; Homma M; Oguro Y; Miyazaki T; Mori K; Uchiyama N; Iwai K; Ohashi A; Hara H; Yoshida S; Cho N
Bioorg Med Chem; 2017 Jul; 25(14):3658-3670. PubMed ID: 28533114
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors.
Elagawany M; Ibrahim MA; Ali Ahmed HE; El-Etrawy ASh; Ghiaty A; Abdel-Samii ZK; El-Feky SA; Bajorath J
Bioorg Med Chem Lett; 2013 Apr; 23(7):2007-13. PubMed ID: 23453843
[TBL] [Abstract][Full Text] [Related]
36. A novel 2,5-diaminopyrimidine-based affinity probe for Bruton's tyrosine kinase.
Zuo Y; Shi Y; Li X; Teng Y; Pan Z
Sci Rep; 2015 Nov; 5():16136. PubMed ID: 26531233
[TBL] [Abstract][Full Text] [Related]
37. Design, synthesis and evaluation of novel 5-phenylpyridin-2(1H)-one derivatives as potent reversible Bruton's tyrosine kinase inhibitors.
Zhao X; Xin M; Huang W; Ren Y; Jin Q; Tang F; Jiang H; Wang Y; Yang J; Mo S; Xiang H
Bioorg Med Chem; 2015 Jan; 23(2):348-64. PubMed ID: 25515957
[TBL] [Abstract][Full Text] [Related]
38. RN486, a selective Bruton's tyrosine kinase inhibitor, abrogates immune hypersensitivity responses and arthritis in rodents.
Xu D; Kim Y; Postelnek J; Vu MD; Hu DQ; Liao C; Bradshaw M; Hsu J; Zhang J; Pashine A; Srinivasan D; Woods J; Levin A; O'Mahony A; Owens TD; Lou Y; Hill RJ; Narula S; DeMartino J; Fine JS
J Pharmacol Exp Ther; 2012 Apr; 341(1):90-103. PubMed ID: 22228807
[TBL] [Abstract][Full Text] [Related]
39. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase.
Pan Z; Scheerens H; Li SJ; Schultz BE; Sprengeler PA; Burrill LC; Mendonca RV; Sweeney MD; Scott KC; Grothaus PG; Jeffery DA; Spoerke JM; Honigberg LA; Young PR; Dalrymple SA; Palmer JT
ChemMedChem; 2007 Jan; 2(1):58-61. PubMed ID: 17154430
[No Abstract] [Full Text] [Related]
40. Clinical potential of targeting Bruton's tyrosine kinase.
Uckun FM
Int Rev Immunol; 2008; 27(1-2):43-69. PubMed ID: 18300055
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]